152 related articles for article (PubMed ID: 23200915)
21. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
[TBL] [Abstract][Full Text] [Related]
22. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
23. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.
Liang H; Yu T; Han Y; Jiang H; Wang C; You T; Zhao X; Shan H; Yang R; Yang L; Shan H; Gu Y
Mol Cancer; 2018 Aug; 17(1):119. PubMed ID: 30098599
[TBL] [Abstract][Full Text] [Related]
24. Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
Bignotti E; Calza S; Tassi RA; Zanotti L; Bandiera E; Sartori E; Odicino FE; Ravaggi A; Todeschini P; Romani C
J Cell Mol Med; 2016 Dec; 20(12):2341-2348. PubMed ID: 27419385
[TBL] [Abstract][Full Text] [Related]
25. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia.
Pradjatmo H
Asian Pac J Cancer Prev; 2015; 16(18):8599-604. PubMed ID: 26745123
[TBL] [Abstract][Full Text] [Related]
26. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
Huang CC; Cheng SH; Wu CH; Li WY; Wang JS; Kung ML; Chu TH; Huang ST; Feng CT; Huang SC; Tai MH
Oncogene; 2019 Apr; 38(17):3201-3215. PubMed ID: 30626939
[TBL] [Abstract][Full Text] [Related]
27. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
28. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
29. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
McDonald ME; Salinas EA; Devor EJ; Newtson AM; Thiel KW; Goodheart MJ; Bender DP; Smith BJ; Leslie KK; Gonzalez-Bosquet J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866519
[TBL] [Abstract][Full Text] [Related]
30. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Gong W; Liu Y; Seidl C; Dreyer T; Drecoll E; Kotzsch M; Bronger H; Dorn J; Magdolen V
PLoS One; 2019; 14(2):e0212968. PubMed ID: 30811511
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
33. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
[TBL] [Abstract][Full Text] [Related]
34. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
Berkel C; Cacan E
Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
[TBL] [Abstract][Full Text] [Related]
35. Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
Lokman NA; Pyragius CE; Ruszkiewicz A; Oehler MK; Ricciardelli C
Transl Res; 2016 May; 171():83-95.e1-2. PubMed ID: 26925708
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
37. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.
Cope L; Wu RC; Shih IeM; Wang TL
Gynecol Oncol; 2013 Mar; 128(3):500-5. PubMed ID: 23200914
[TBL] [Abstract][Full Text] [Related]
38. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.
Yang D; Sun Y; Hu L; Zheng H; Ji P; Pecot CV; Zhao Y; Reynolds S; Cheng H; Rupaimoole R; Cogdell D; Nykter M; Broaddus R; Rodriguez-Aguayo C; Lopez-Berestein G; Liu J; Shmulevich I; Sood AK; Chen K; Zhang W
Cancer Cell; 2013 Feb; 23(2):186-99. PubMed ID: 23410973
[TBL] [Abstract][Full Text] [Related]
39. Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer.
Liang H; Zhao X; Wang C; Sun J; Chen Y; Wang G; Fang L; Yang R; Yu M; Gu Y; Shan H
Mol Cancer; 2018 Jun; 17(1):96. PubMed ID: 29929545
[TBL] [Abstract][Full Text] [Related]
40. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]